Relative dose intensity of gemcitabine-nab-paclitaxel combination as second-line or more in locally advanced or metastatic pancreatic adenocarcinoma
Our results suggest that the level of GNP exposure, at a predefined RDI threshold of 70 %, had no significant effect on survival in our patients treated in L2+ for a/mPA. Alternative GNP regimens may be evaluated in patients undergoing L2+ treatment for a/mPA.
Authors
- Marie Dutherage
- André Gillibert (ORCID: https://orcid.org/0000-0002-0797-1817)
- Lilian Schwarz (ORCID: https://orcid.org/0000-0001-6726-8755)
- Adrien Grancher
- Michel Pierre
- Frédéric Di Fiore (ORCID: https://orcid.org/0000-0001-5237-2971)
- David Sefrioui
- Virginie Vernon
- Leila Tagemouati
Institutions
- Centre Hospitalier Universitaire de Rouen (FR)
- Université de Rouen Normandie (FR)
Publication Details
- Journal
- Clinics and Research in Hepatology and Gastroenterology
- Published
- 2025-03-30
- DOI
- https://doi.org/10.1016/j.clinre.2025.102583
- Citations
- 2
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09